miRNA与药物反应个体差异

摘要/Abstract

摘要： 目前关于药物反应个体差异研究集中在药物代谢和药物靶点基因的单核苷酸多态性位点(SNPs)和其他基因突变(例如拷贝数的变化)的表型效应,而仅分析DNA序列不能完全解释药物反应个体差异。miRNA的发现,为其提供了新的研究方向。miRNA是一类内源性的非编码小RNA,其与靶基因mRNA 3'非翻译区(3'UTR)互补结合,引起mRNA切割或翻译抑制,从而在转录后水平下调基因表达。miRNA可负调控大量人类基因的表达,其中包括许多药物疗效相关基因。越来越多的研究结果表明,miRNA是导致药物反应个体差异的又一重要因素。本文从miRNA调控药物代谢、药物转运和药物靶点,miRNA及其结合位点多态性等方面对miRNA在药物反应个体差异中所起作用进行综述。

关键词: miRNA, 个体差异, 药物反应, 基因多态性

Abstract: The current focus of interindividual differences in drug response is primarily studying on the phenotypic effects of SNPs and other genetic variations (such as copy number variations) in drug-metabolizing and drug-target genes, which cannot fully explain the interindividual variations in drug response. miRNAs are non-coding endogenous short RNAs which binding to the 3'untranslated region (3'UTR) of its target gene and marking them for degradation and/or translation inhibition at the post- transcriptional level. miRNA can negative control a large human gene expression, including many pharmacokinetics and pharmacodynamics genes, consequently, miRNA play very important roles in altered therapeutical efficacy. Expression levels of drug metabolism, drug transport and drug targets can be regulated by miRNA. miRNA and its binding site polymorphisms can influence gene expression, thus affecting drug response. In this review, we summarized the regulation of miRNA in drug therapy.

Key words: miRNA, Interindividual difference, Drug response, Gene polymorphisms

中图分类号:

R968

郭瑜, 周宏灏, 刘昭前. miRNA与药物反应个体差异[J]. 中国临床药理学与治疗学, 2013, 18(4): 443-448.

GUO Yu, ZHOU Hong-hao, LIU Zhao-qian. MiRNA and interindividual difference in drug response[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(4): 443-448.

参考文献

[1] Kim D, Rossi J. RNAi mechanisms and applications[J]. Biotechniques, 2008, 44(5): 613-616.
[2] Thai TH, Christiansen PA, Tsokos GC. Is there a link between dysregulated miRNA expression and disease[J]? Discov Med, 2009, 10(52): 184-194.
[3] Zhang B, Farwell MA. MicroRNAs: a new emerging class of players for disease diagnostics and gene therapy[J]. J Cell Mol Med, 2008, 12(1): 3-21.
[4] Rukov JL, Vinther J, Shomron N. Pharmacogenomics genes show varying perceptibility to microRNA regulation[J]. Pharmacogenet Genomics, 2011, 21(5): 251-262.
[5] Terao M, Fratelli M, Kurosaki M, et al. Induction of miR-21 by retinoic acid in estrogen receptor- positive breast carcinoma cells: biological correlates and molecular targets[J]. J Biol Chem, 2011, 286(5): 4027-4042.
[6] Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact[J]. Drug Metab Rev, 2009, 41(2): 289-295.
[7] Ramamoorthy A, Skaar TC. In silico identification of microRNAs predicted to regulate the drug metabolizing cytochrome P450 genes[J]. Drug Metab Lett, 2011, 5(2): 126-131.
[8] Tsuchiya Y, Nakajima M, Takagi S, et al. MicroRNA regulates the expression of human cytochrome P450 1B1[J]. Cancer Res, 2006, 66(18): 9090-9098.
[9] Mohri T, Nakajima M, Fukami T, et al. Human CYP2E1 is regulated by miR-378[J]. Biochem Pharmacol, 2010, 79(7): 1045-1052.
[10] Kalscheuer S, Zhang X, Zeng Y, et al. Differential expression of microRNAs in early-stage neoplastic transformation in the lungs of F344 rats chronically treated with the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone[J]. Carcinogenesis, 2008, 29(12): 2394-2399.
[11] Komagata S, Nakajima M, Takagi S, et al. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b[J]. Mol Pharmacol, 2009, 76(4): 702-709.
[12] Mutallip M, Nohata N, Hanazawa T, et al. Glutathione S-transferase P1 (GSTP1) suppresses cell apoptosis and its regulation by miR-133alpha in head and neck squamous cell carcinoma (HNSCC)[J]. Int J Mol Med, 2011, 27(3): 345-352.
[13] Adams BD, Furneaux H, White BA, The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines[J]. Mol Endocrinol, 2007, 21(5): 1132-1147.
[14] Pandey DP, Picard D. miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA[J]. Mol Cell Biol, 2009, 29(13): 3783-3790.
[15] Takagi S, Nakajima M, Mohri T, et al. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4[J]. J Biol Chem, 2008, 283(15): 9674-9680.
[16] Ji J, Zhang J, Huang G, et al. Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation[J]. FEBS Lett, 2009, 583(4): 759-766.
[17] Pan YZ, Gao W, Yu AM. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting[J]. Drug Metab Dispos, 2009, 37(10): 2112-2117.
[18] Huang Y. Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy[J]. Cancer Metastasis Rev, 2007, 26(1): 183-201.
[19] Candelaria M, de la Cruz-Hernández E, Pérez-Cárdenas E, et al. Pharmacogenetics and pharmaco- epigenetics of gemcitabine[J]. Med Oncol, 2010, 27(4): 1133-1143.
[20] Liang Z, Wu H, Xia J, et al. Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1[J]. Biochem Pharmacol, 2010. 79(6): 817-824.
[21] Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs down-regulate large numbers of target mRNAs[J]. Nature, 2005, 433(7027): 769-773.
[22] Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers[J]. Nature, 2005, 435(7043): 834-838.
[23] Hu Z, Chen X, Zhao Y, et al. Serum microRNA signatures identified in a genome wide serum microRNA expression profiling predict survival of non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(10): 1721-1726.
[24] Kong L, Zhu J, Han W, et al. Significance of serum microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical study[J]. Acta Diabetol, 2011, 48(1): 61-69.
[25] Brase JC, Wuttig D, Kuner R, et al. Serum microRNAs as non-invasive biomarkers for cancer[J]. Mol Cancer Ther, 2010, 9: 306.
[26] Klein TE, Chang JT, Cho MK, et al. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base[J]. Pharmacogenomics J, 2001, 1(3): 167-170.
[27] To KH, Pajovic S, Gallie BL, et al. Regulation of p14ARF expression by miR-24: a potential mechanism compromising the p53 response during retinoblastoma development[J]. BMC Cancer, 2012, 12: 69.
[28] Kurokawa K, Tanahashi T, Iima T, et al. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells[J]. J Gastroenterol, 2012, 47(8): 883-895.
[29] Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients[J]. J Biol Chem, 2012, 287(37): 31298-310.
[30] Long JM, Ray B, Lahiri DK. MicroRNA-153 physiologically inhibits expression of amyloid-beta precursor protein in cultured human fetal brain cells and is dysregulated in a subset of Alzheimer disease patients[J]. J Biol Chem, 2012, 287(37): 31298-310.
[31] Li Y, Zhu X, Gu J, et al. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis[J]. Cancer Sci, 2010, 101(4): 948-954.
[32] Xu K, Liang X, Shen K, et al. MiR-222 modulate multidrug resistance in human colorectal carcinoma by down-regulating ADAM-17[J]. Exp Cell Res, 2012, 318(17): 2168-77.
[33] Xu K, Liang X, Shen K, et al. MiR-297 modulate multidrug resistance in human colorectal carcinoma by down-regulating MRP-2[J]. Biochem J, 2012, 446(2): 291-300.
[34] Duan R, Park C, Jin P. Single nucleotide polymorphhism associated with mature miR-125a alters the processing of pri-miRNA[J]. Hum Mol Genet, 2007, 16(9): 1124-1131.
[35] Landi D, Gemignani F, Naccarati A. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer[J]. Carcinogenesis, 2008, 29(3): 579-584.
[36] Yamano Y, Uzawa K, Saito K, et al. Identification of cisplatin-resistance related genes in head and neck squamous cell carcinoma[J]. Int J Cancer, 2010, 126(2): 437-449.
[37] Liang D. Genetic variants in microRNA biosynthesis pathways and binding sites modify ovarian cancer risk, survival and treatment response[J]. Cancer Res, 2010, 70(23): 9765-9776.
[38] Mishra PJ, Humeniuk R, Mishra PJ, et al. A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance[J]. Proc Natl Acad Sci U S A, 2007, 104(33): 13513-13518.